David B. Weiner, of the Wistar Institute, and his laboratory, created a new therapeutic design for glioblastoma, the deadliest form of brain cancer.
A team at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute completed its first gene therapy for a patient with hemophilia B, the first at an adult medical center in Ohio.
RWE and phase I data support the role of Orserdu for ER+, HER2- advanced or metastatic breast cancer
The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
A new nationwide survey of more than 750 radiation oncologists confirms that prior authorization harms people with cancer by causing treatment delays, abandoned treatments, hospitalizations and patient deaths.
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
A cancer therapy that prompts the body’s immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke. A possible explanation for this side effect is that the treatment interferes with immune regulation in the heart’s largest blood vessels, a new study suggests.
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, a treatment for multiple myeloma. Their study was published this month in the journal Blood Neoplasia.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
Laboratory experiments with cancer cells reveal two ways in which tumors evade chemotherapy drugs designed to starve and kill them, a new study in Nature Metabolism shows.
The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.
